139 related articles for article (PubMed ID: 7957889)
1. Use of a monoclonal antibody to detect DNA damage caused by the anticancer drug cis-diamminedichloroplatinum (II) in vivo and in vitro.
Chao CC; Shieh TC; Huang H
FEBS Lett; 1994 Oct; 354(1):103-9. PubMed ID: 7957889
[TBL] [Abstract][Full Text] [Related]
2. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells.
Chao CC
Eur J Pharmacol; 1994 Aug; 268(3):347-55. PubMed ID: 7805758
[TBL] [Abstract][Full Text] [Related]
3. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair.
Chao CC
Mol Pharmacol; 1994 Jun; 45(6):1137-44. PubMed ID: 8022407
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair.
Chao CC
Eur J Pharmacol; 1996 Jun; 305(1-3):213-22. PubMed ID: 8813556
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).
Sundquist WI; Lippard SJ; Stollar BD
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8225-9. PubMed ID: 2446320
[TBL] [Abstract][Full Text] [Related]
6. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo.
Mello JA; Lippard SJ; Essigmann JM
Biochemistry; 1995 Nov; 34(45):14783-91. PubMed ID: 7578087
[TBL] [Abstract][Full Text] [Related]
7. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA.
Yaneva J; Leuba SH; van Holde K; Zlatanova J
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13448-51. PubMed ID: 9391045
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.
Donahue BA; Augot M; Bellon SF; Treiber DK; Toney JH; Lippard SJ; Essigmann JM
Biochemistry; 1990 Jun; 29(24):5872-80. PubMed ID: 2383564
[TBL] [Abstract][Full Text] [Related]
9. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.
Liedert B; Pluim D; Schellens J; Thomale J
Nucleic Acids Res; 2006 Mar; 34(6):e47. PubMed ID: 16571898
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by arsenite of anticancer drug cis-diamminedichloroplatinum(II) induced DNA repair and drug resistance in HeLa cells.
Chao CC
Environ Toxicol Pharmacol; 1996 May; 1(3):199-205. PubMed ID: 21781682
[TBL] [Abstract][Full Text] [Related]
11. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts.
Malina J; Kasparkova J; Natile G; Brabec V
Chem Biol; 2002 May; 9(5):629-38. PubMed ID: 12031669
[TBL] [Abstract][Full Text] [Related]
12. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
13. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
Tilby MJ; Johnson C; Knox RJ; Cordell J; Roberts JJ; Dean CJ
Cancer Res; 1991 Jan; 51(1):123-9. PubMed ID: 1703029
[TBL] [Abstract][Full Text] [Related]
14. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication.
Heiger-Bernays WJ; Essigmann JM; Lippard SJ
Biochemistry; 1990 Sep; 29(36):8461-6. PubMed ID: 2174701
[TBL] [Abstract][Full Text] [Related]
15. Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II).
Clugston CK; McLaughlin K; Kenny MK; Brown R
Cancer Res; 1992 Nov; 52(22):6375-9. PubMed ID: 1423284
[TBL] [Abstract][Full Text] [Related]
16. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA; Acharya S; Fishel R; Essigmann JM
Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
[TBL] [Abstract][Full Text] [Related]
17. Apparent alterations in the early stage of excision repair of UV-induced DNA damages in a HeLa mutant cell line that is resistant to genotoxic stresses.
Chao CC; Huang SL
Mutat Res; 1993 Sep; 303(1):19-27. PubMed ID: 7690902
[TBL] [Abstract][Full Text] [Related]
18. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
19. Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts.
Calsou P; Frit P; Salles B
Nucleic Acids Res; 1992 Dec; 20(23):6363-8. PubMed ID: 1475197
[TBL] [Abstract][Full Text] [Related]
20. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
Kaspárková J; Brabec V
Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
